Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036075 · ClinicalTrials.gov registry record · Phase 2

Study Using CP-461 to Treat Advanced Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
2
Study locations

NCT00036075 is a Phase 2 study of Prostate Cancer that has completed, run by Astellas Pharma. The registered enrollment target is 25 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00036075, a Phase 2 study of Prostate Cancer, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to investigate whether an investigational drug, CP-461, is safe and effective for the treatment of patients with prostate cancer and who have measurable disease.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG CP-461

Study Locations (2)

New York

  • Columbia Presbyterian Medical Center - New York

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2001-08
Est. Completion 2005-12
Phase Phase 2

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00036075

The ClinicalTrials.gov registry entry for NCT00036075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which CP-461 is the first listed.

NCT00036075 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Washington.

Frequently Asked Questions

What is clinical trial NCT00036075 about?

NCT00036075 is a clinical study titled "Study Using CP-461 to Treat Advanced Prostate Cancer". The purpose of this study is to investigate whether an investigational drug, CP-461, is safe and effective for the treatment of patients with prostate cancer and who have measurable disease.

What is the current status of trial NCT00036075?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2001-08. Estimated completion is 2005-12.

What conditions does trial NCT00036075 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00036075?

The interventions under investigation include: CP-461 (DRUG).

Who is sponsoring clinical trial NCT00036075?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00036075 being conducted?

This trial has 2 study locations across New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.